Mobile

A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreate...

Update Il y a 4 ans
Reference: EUCTR2006-006050-10

A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to determine the overall combined complete response rate (CR rate) (defined in this protocol as the combination of complete response [CR, including sCR and nCR]) following induction treatment with VDT or VDTC in subjects with newly diagnosed symptomatic multiple myeloma who are candidates for HDT/SCT.

Inclusion criteria

  • Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation

Links